Treatment of Pulmonary Mucormycosis in Pre-existing Renal Compromise / Renal Failure
Pulmonary mucormycosis in a patient with pre-existing renal compromise or renal failure requires a treatment strategy that addresses both the severity of the fungal infection and the need to protect kidney function. Antifungal selection is directly shaped by the degree of renal impairment.
This protocol applies to pulmonary mucormycosis presenting in the context of pre-existing renal compromise or renal failure. The impaired renal status is a critical determinant of which antifungal agents can be safely used, as nephrotoxic options must be avoided. Evidence supports the use of specific azole antifungals that are effective in this population without imposing additional burden on the kidneys.
The approach centres on early, complete surgical debridement combined with systemic azole antifungal therapy — a class of agents demonstrated to be effective specifically in the setting of renal impairment. The full protocol details agent selection, the criteria governing transitions between administration routes, and the complete sequenced regimen.
- Stable disease or partial response on imaging at response assessment
- Regular imaging-based reassessment to guide continuation or transition of therapy
- In case of renal failure, posaconazole or isavuconazole were shown to be effective.
- The guideline group strongly supports an early complete surgical treatment for mucormycosis whenever possible, in addition to systemic antifungal treatment.
- There is moderate support for intravenous treatment until stable disease is achieved.